A study promoted by SOLTI and published in Nature Communications describes the tumour biology associated with the activity of the drug patritumab der1
This year, FERO will contribute €200,000, with which it will seek to provide structural and sustained support for the Molecular Diagnostics Programme1
On 27 June 2024, a social return event was held at the TV3 facilities, thanking the public for the television marathon devoted to cancer.
Dr. Llovet (Clínic-IDIBAPS) and Dr. Bustelo (CSIC-University of Salamanca) coordinate the ASPIRE-AECC project, which includes 15 hospitals to conduct1
A study published recently in the journal Clinical Cancer Research identified biomarkers that can predict the response to CAR T-cell therapy targetin1
A study led by researchers from the Clínic-IDIBAPS paves the way for the design and optimization of CAR T-cell therapy for greater effectiveness in t1
The goal of the current campaign is to reach 1,000 hours of cancer research. For each book read, 10 minutes of research, and for every six books, one1
Researchers from the Hospital Clínic-IDIBAPS have published a review in Nature Reviews Clinical Oncology about the adjuvant and neoadjuvant treatment1
The DEFINITIVE project, led by IDIBAPS, will be conducted across 44 hospitals in a total of 7 European and associated countries to demonstrate that u1
An international team, co-led by the Hospital Clínic-IDIBAPS, has identified four biomarkers that determine the risk of the recurrence of this cancer1
